Duration of Vi antibodies in participants vaccinated with Typhim Vi (Typhoid Vi polysaccharide vaccine) in an area not endemic for typhoid fever

被引：17

作者：

Froeschle, James E. ^{[1
]}

Decker, Michael D. ^{[1
,2
]}

机构：

[1] Sanofi Pasteur, Sci & Med Affairs, Swiftwater, PA 18370 USA

[2] Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37212 USA

来源：

VACCINE | 2010年 / 28卷 / 06期

关键词：

Vaccines; Vi polysaccharide vaccine; Typhoid; Bacterial Polysaccharides; CAPSULAR POLYSACCHARIDE; SALMONELLA-TYPHI; IMMUNIZATION; SAFETY; IMMUNOGENICITY; PREVENTION;

D O I：

10.1016/j.vaccine.2009.11.051

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

After a single injection of Typhim Vi (R) (typhoid Vi polysaccharide vaccine), serum antibody concentrations were monitored for 3 years in 37 adults who resided where typhoid fever was not endemic. Anti-Vi antibody concentrations declined progressively during the study, to levels that support the current US recommendation for revaccination every 2 years. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：1451 / 1453

页数：3

共 15 条

[1] PREVENTION OF TYPHOID-FEVER IN NEPAL WITH THE VI CAPSULAR POLYSACCHARIDE OF SALMONELLA-TYPHI - A PRELIMINARY-REPORT [J].

ACHARYA, IL ;

LOWE, CU ;

THAPA, R ;

GURUBACHARYA, VL ;

SHRESTHA, MB ;

CADOZ, M ;

SCHULZ, D ;

ARMAND, J ;

BRYLA, DA ;

TROLLFORS, B ;

CRAMTON, T ;

SCHNEERSON, R ;

ROBBINS, JB .

NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (18) :1101-1104

[2]

[Anonymous], 2008, Wkly Epidemiol Rec, V83, P49

[3] Postmarketing safety surveillance for typhoid fever vaccines from the Vaccine Adverse Event Reporting System, July 1990 through June 2002 [J].

Begier, EM ;

Burwen, DR ;

Haber, P ;

Ball, R .

CLINICAL INFECTIOUS DISEASES, 2004, 38 (06) :771-779

[4] Experience with Salmonella typhi Vi capsular polysaccharide vaccine [J].

Hessel, L ;

Debois, H ;

Fletcher, M ;

Dumas, R .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1999, 18 (09) :609-620

[5] Persistence of antibodies to the Salmonella typhi Vi capsular polysaccharide vaccine in South African school children ten years after immunization. [J].

Keddy, KH ;

Klugman, KP ;

Hansford, CF ;

Blondeau, C ;

le Cam, NNB .

VACCINE, 1999, 17 (02) :110-113

[6] CLINICAL AND SEROLOGICAL RESPONSES FOLLOWING PRIMARY AND BOOSTER IMMUNIZATION WITH SALMONELLA-TYPHI-VI CAPSULAR POLYSACCHARIDE VACCINES [J].

KEITEL, WA ;

BOND, NL ;

ZAHRADNIK, JM ;

CRAMTON, TA ;

ROBBINS, JB .

VACCINE, 1994, 12 (03) :195-199

[7] Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization [J].

Klugman, KP ;

Koornhof, HJ ;

Robbins, JB ;

LeCam, NN .

VACCINE, 1996, 14 (05) :435-438

[8]

KLUGMAN KP, 1987, LANCET, V2, P1165

[9] Safety of typhim Vi vaccine in a postmarketing observational study [J].

Marcus, Leonard C. ;

Froeschle, James E. ;

Hill, David R. ;

Wolfe, Martin S. ;

Maus, Diane ;

Connor, Bradley ;

Acosta, Alberto M. ;

Rensimer, Edward R. ;

Roberts, Alan ;

Dardick, Kenneth .

JOURNAL OF TRAVEL MEDICINE, 2007, 14 (06) :386-391

[10] Outbreak of typhoid fever in vaccinated members of the French Armed Forcesin the Ivory Coast [J].

Michel, R ;

Garnotel, E ;

Spiegel, A ;

Morillon, M ;

Saliou, P ;

Boutin, JP .

EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2005, 20 (07) :635-642

← 1 2 →